Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
3.730
+0.070 (1.91%)
At close: Nov 6, 2026, 4:00 PM EST
3.688
-0.042 (-1.13%)
After-hours: Nov 6, 2026, 7:30 PM EST
Kyntra Bio Employees
Kyntra Bio had 34 employees as of December 31, 2025. The number of employees decreased by 191 or 84.89% compared to the previous year. That makes Kyntra Bio the 36,671st largest employer in the world and 5,053rd in the United States.
Employees
34
Change (1Y)
-191
Growth (1Y)
-84.89%
Revenue / Employee
$135,765
Profits / Employee
$5,388,000
Market Cap
15.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 34 | -191 | -84.89% |
| Dec 31, 2024 | 225 | -261 | -53.70% |
| Dec 31, 2023 | 486 | -106 | -17.91% |
| Dec 31, 2022 | 592 | 26 | 4.59% |
| Dec 31, 2021 | 566 | -33 | -5.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| Acumen Pharmaceuticals | 61 |
| aTyr Pharma | 60 |
| Citius Pharmaceuticals | 23 |
| Bolt Biotherapeutics | 23 |
| NewcelX | 12 |
| Allarity Therapeutics | 8 |
| Akari Therapeutics, | 6 |
KYNB News
- 26 days ago - Kyntra Bio initiated with a Buy at Maxim on mCRPC potential - TheFly
- 26 days ago - Kyntra Bio initiated with a Buy at Maxim - TheFly
- 5 weeks ago - Kyntra Bio appoints Singer to its board of directors - TheFly
- 5 weeks ago - Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential - TheFly
- 7 weeks ago - Kyntra Bio initiated with a Buy at Lake Street - TheFly
- 7 weeks ago - Kyntra Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire